FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892930639> ?p ?o ?g. }

• W2892930639 abstract "Background: In Malaysia, breast cancer is the most common cancer in females and also the first most common cancer among population regardless of gender. Trastuzumab is used for the treatment of early-stage breast cancer that is HER2 positive. Although this treatment has been routinely used, there are still controversial on the duration of the addition of trastuzumab to the chemotherapy regimen. Aim: To assess the safety and effectiveness of trastuzumab as an adjuvant in early breast cancer patients through a systematic review. Methods: Electronic databases were searched through the Ovid interface. The titles and abstracts were screened against the inclusion and exclusion criteria and then evaluated the selected full-text articles. Results: There was high level of evidence to suggest that the risk of congestive heart failure (CHF) was significantly higher in patients treated with trastuzumab compared with nontrastuzumab control group (RR 5.11; 90% CI: 3.00-8.72, P < 0.00001) in one Cochrane review, (RR 3.19; 95% CI: 2.03-5.02, P < 0.00001) in one systematic review and meta-analysis. Evidence also suggested that the risk was significantly higher with longer duration of treatment (> 6 months) RR 5.39; 90% CI: 3.56-8.17, P < 0.00001. The overall survival (OS) significantly favored trastuzumab-containing regimen over nontrastuzumab control group, (HR 0.66; 95% CI: 0.55-0.77, P < 0.00001). In terms of duration, subgroup analysis reported that the overall survival (OS) significantly favored trastuzumab-containing regimen over nontrastuzumab control group trials where trastuzumab was given longer (> 6 months), HR 0.67; 95% CI: 0.57-0.80, P < 0.00001. In the trials that gave trastuzumab and chemotherapy concurrently, HR significantly favored trastuzumab-containing regimens (HR 0.64; 95% CI: 0.57-0.80, P < 0.00001). The evidence from Cochrane systematic review suggests that disease-free survival (DFS) favored trastuzumab-containing regimen over the nontrastuzumab control group (HR 0.60; 95% CI: 0.50-0.71, P < 0.00001). In terms of duration of treatment, there was no significant difference in DFS when trastuzumab was used for less than six months or more than six months. The DFS significantly favored trastuzumab-containing regimen over nontrastuzumab control group when used either concurrently or sequentially. Limited evidence to suggest that two years duration of adjuvant trastuzumab was not more effective that one year of treatment. However, six months treatment with trastuzumab failed to show that it was noninferior to twelve months of trastuzumab. There was limited retrievable evidence to suggest that there is no significant difference in OS and DFS between the twelve months regimen and 9-week regimen for trastuzumab. Conclusion: Despite the higher rates of cardiac events, twelve months of adjuvant trastuzumab was suggested as the standard of care. However, other issues including cost and cost-effectiveness should be considered." @default.
• W2892930639 created "2018-10-05" @default.
• W2892930639 creator A5007472903 @default.
• W2892930639 creator A5047262127 @default.
• W2892930639 creator A5091214046 @default.
• W2892930639 date "2018-10-01" @default.
• W2892930639 modified "2023-09-25" @default.
• W2892930639 title "Trastuzumab as An Adjuvant Therapy for Early Breast Cancer" @default.
• W2892930639 doi "https://doi.org/10.1200/jgo.18.31500" @default.
• W2892930639 hasPublicationYear "2018" @default.
• W2892930639 type Work @default.
• W2892930639 sameAs 2892930639 @default.
• W2892930639 citedByCount "0" @default.
• W2892930639 crossrefType "journal-article" @default.
• W2892930639 hasAuthorship W2892930639A5007472903 @default.
• W2892930639 hasAuthorship W2892930639A5047262127 @default.
• W2892930639 hasAuthorship W2892930639A5091214046 @default.
• W2892930639 hasBestOaLocation W28929306391 @default.
• W2892930639 hasConcept C121608353 @default.
• W2892930639 hasConcept C126322002 @default.
• W2892930639 hasConcept C142724271 @default.
• W2892930639 hasConcept C143998085 @default.
• W2892930639 hasConcept C204787440 @default.
• W2892930639 hasConcept C2777596629 @default.
• W2892930639 hasConcept C2777863537 @default.
• W2892930639 hasConcept C2779786085 @default.
• W2892930639 hasConcept C2781413609 @default.
• W2892930639 hasConcept C2908647359 @default.
• W2892930639 hasConcept C29456083 @default.
• W2892930639 hasConcept C530470458 @default.
• W2892930639 hasConcept C71924100 @default.
• W2892930639 hasConcept C99454951 @default.
• W2892930639 hasConceptScore W2892930639C121608353 @default.
• W2892930639 hasConceptScore W2892930639C126322002 @default.
• W2892930639 hasConceptScore W2892930639C142724271 @default.
• W2892930639 hasConceptScore W2892930639C143998085 @default.
• W2892930639 hasConceptScore W2892930639C204787440 @default.
• W2892930639 hasConceptScore W2892930639C2777596629 @default.
• W2892930639 hasConceptScore W2892930639C2777863537 @default.
• W2892930639 hasConceptScore W2892930639C2779786085 @default.
• W2892930639 hasConceptScore W2892930639C2781413609 @default.
• W2892930639 hasConceptScore W2892930639C2908647359 @default.
• W2892930639 hasConceptScore W2892930639C29456083 @default.
• W2892930639 hasConceptScore W2892930639C530470458 @default.
• W2892930639 hasConceptScore W2892930639C71924100 @default.
• W2892930639 hasConceptScore W2892930639C99454951 @default.
• W2892930639 hasLocation W28929306391 @default.
• W2892930639 hasOpenAccess W2892930639 @default.
• W2892930639 hasPrimaryLocation W28929306391 @default.
• W2892930639 hasRelatedWork W1963884068 @default.
• W2892930639 hasRelatedWork W2014088170 @default.
• W2892930639 hasRelatedWork W2018808601 @default.
• W2892930639 hasRelatedWork W2056435674 @default.
• W2892930639 hasRelatedWork W2103725500 @default.
• W2892930639 hasRelatedWork W2398495979 @default.
• W2892930639 hasRelatedWork W2407758792 @default.
• W2892930639 hasRelatedWork W2975028547 @default.
• W2892930639 hasRelatedWork W965056516 @default.
• W2892930639 hasRelatedWork W2199341048 @default.
• W2892930639 isParatext "false" @default.
• W2892930639 isRetracted "false" @default.
• W2892930639 magId "2892930639" @default.
• W2892930639 workType "article" @default.